New advances in optogenetics and stem cell research are giving scientists promising new paths to restore sight for millions living with blindness.

More than 20 million people in the U.S. live with visual impairment caused by conditions like age‑related macular degeneration (AMD), retinitis pigmentosa (RP), glaucoma, cataracts, and diabetic retinopathy. Many forms of blindness still have no cure. But new technologies—including gene‑based light‑sensing strategies and cell‑replacement therapies—are now being tested in clinical trials, offering new hope for restoring vision.

AMD

Age‑related macular degeneration destroys the macula, which controls central vision. Retinitis pigmentosa damages photoreceptors, causing night blindness, tunnel vision, and eventual vision loss. Other diseases, including cataracts, glaucoma, and diabetic retinopathy, can also strip people of vision.

Many of these conditions have no cure, but science has progressed. Researchers are testing two fast‑moving technologies: optogenetics and stem cells.

What is optogenetics?

Optogenetics is a technique that uses genetic engineering to make cells respond to light. Scientists can turn nerve cells on or off by adding light‑sensitive proteins called opsins. When exposed to certain wavelengths of light, these modified cells send signals that control their activity.

Animal studies that used optogenetics to restore sight have shown promise. RetroSense Therapeutics developed a gene therapy that targets retinal ganglion cells and turns them into light‑sensing cells. A clinical trial is underway in patients with RP. The goal is modest: move patients from zero vision to some vision and ensure the approach is safe.

Stem cell treatments in development

Researchers are also testing stem cell therapies for RP and AMD. They use pluripotent stem cells and fetal‑derived retinal progenitor cells to replace or support damaged retinal cells. A common strategy for AMD is to generate retinal pigment epithelial (RPE) cells and transplant them into patients to keep the retina healthy.

Ocata Therapeutics used embryonic‑stem‑cell‑derived RPE cells in early AMD trials and saw some vision improvement with no major side effects. In Japan, researchers used RPE sheets derived from iPS cells. The trial paused after detecting a potential mutation in lab‑grown cells, highlighting the safety challenges of stem‑cell‑based therapies.

CIRM is supporting several trials. One team at UC Irvine is using fetal retinal progenitor cells to help protect remaining photoreceptors in RP patients. Another team at USC and UC Santa Barbara is testing RPE sheets grown on synthetic scaffolds for AMD.

Optogenetics or stem cells?

Each technology faces challenges. Optogenetics requires viruses to deliver opsin genes to the right cells. These engineered cells may not adapt well to changing light levels, so patients may need special light‑adjusting glasses.

Stem cell therapies pose different hurdles. Pluripotent stem cells can form tumors if not properly controlled. Regulatory barriers also slow and complicate clinical adoption.

Which will reach patients first—optogenetics or stem cells? The answer is that it doesn’t matter. What matters is that both continue advancing. With sustained progress, one—or possibly both—could offer safe, effective treatments to restore sight for people living with blindness.

Unfortunately, there is no cure for many forms of blindness, but science has advanced enough that researchers are testing multiple technologies in human clinical trials to improve sight in blind patients. Today, I’ll talk about two technologies: optogenetics and stem cells, both innovative techniques that have made rapid progress in recent years.